Many people in our state struggle with the cost of prescription medications – Oregon Prescription Drug Affordability Board (PDAB) is gathering real stories to understand how these prices affect everyday life.
In February, we shared that PDAB was working on identifying a list of prescription drugs for review at upcoming community forums. This year, PDAB is reviewing these prescription drugs to learn more about their affordability and their impact on Oregonians:
- Jardiance
- Mounjaro
- Ozempic
- Humulin R U-500
- Keytruda
- Verzenio
- Xeljanz
- Ocrevus
- Skyrizi
- Tremfya
- Xolair
If you, someone you care for, or the community you serve has been affected by any of these medications—whether in health, cost, or access—your voice matters. Your feedback will help PDAB better understand the challenges people face and support future decisions.
The board is inviting feedback from patients, caregivers, advocacy groups, medical professionals, manufacturers, safety‑net clinics, pharmacy benefit managers, and health plan insurers. Anyone who has experience with the medications under review is welcome to share.
You can find the feedback forms on the PDAB website. You can also use the buttons to the right to choose the form that fits your situation. The form for patients, caregivers, and advocacy groups is available in both English and Spanish.
Forms will remain open until the board completes its initial review process in the fall.
Thank you for taking the time to share your experience. Your input helps make Oregon’s health care system stronger for everyone.